Identification of serological markers of protection and risk for dengue vaccines and natural infection
鉴定登革热疫苗和自然感染的保护和风险的血清学标记
基本信息
- 批准号:10638037
- 负责人:
- 金额:$ 69.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAntibodiesAntibody ResponseAntibody-Dependent EnhancementAntigenic SpecificityAntigenic VariationAttenuatedAutomobile DrivingB-LymphocytesBiologicalBiological AssayCollectionComplement ActivationCountryDengueDengue InfectionDengue VaccineDengue VirusDengvaxiaDevelopmentDimensionsDiseaseEffectivenessEvaluationFailureGrantHumanImmuneImmune responseImmunityImmunologic MarkersImmunological ModelsImmunologicsImmunology procedureIndividualInfectionLabelLicensingLicensureLife Cycle StagesLinkLongterm Follow-upMeasuresMediatingMemoryMemory B-LymphocyteModelingOutcomeParticipantPerformancePeripheral Blood Mononuclear CellPhilippinesPopulationPublic HealthRecording of previous eventsRiskRisk AssessmentRisk MarkerRoleSafetySamplingSeveritiesSeverity of illnessSystemT cell responseT-LymphocyteThailandTimeUnited States National Institutes of HealthVaccinatedVaccinationVaccineeVaccinesWorkantibody-dependent cell cytotoxicitycohortdesigndisorder riskepidemiology studyexperiencefollow-upimmunological diversityimprovedinfection riskmathematical modelpathogenphase 3 testingrecruitresponseserological markerunvaccinatedvaccine candidatevaccine developmentvaccine evaluationvaccine trial
项目摘要
Project Summary
Dengue remains stubbornly endemic in many countries. Vaccine development efforts have been hampered by
a poor understanding of the immune response. We do know that pre-existing immunity from vaccination or
historic infections is key to driving disease risk, however, accurate markers of risk or protection are lacking,
including how they change over multiple years. Less is known about the role of non-neutralizing antibody
functions, such as antibody-dependent cell cytotoxicity, and antibody-dependent enhancement in driving disease
risk. Neutralizing and non-neutralizing antibody responses have not been characterized alongside cellular
immune responses that have been identified to be associated with risk of illness. Here, we will expand upon
previous work on the diversity of neutralization responses to specifically add characterization of non-neutralizing
antibody responses and cellular immune responses from natural infection and vaccination using samples taken
from the same individuals over numerous time points. These samples come from cohorts that had regular
collection of sera and PBMC and were followed for instances of infection and illness, many of which severe. This
includes a cohort of individuals that were vaccinated by the only licensed dengue vaccine, a cohort followed for
13 years. We also have access to samples from individuals vaccinated with another candidate vaccine followed
over five years. Finally, we will re-recruit cohort participants to provide samples 23 years after their participation
to investigate long term responses after infections. We will measure multiple non-neutralizing and neutralizing
responses to a diverse set of dengue viruses a wide range of antibody measures as well as a limited set of
cellular immune responses, providing a multi-dimensional, systems characterization of humoral and cellular
immune responses. We will use this multi-dimensional measure and mathematical models to reconstruct full
infection histories and immune dynamics. These efforts will provide a set of correlates of protection/risk of illness
and infection that can be used to assess risk in vaccine trials and epidemiological studies. These mechanistic
models will be generally useful to infer dynamics of immune responses to antigenically variable pathogens and
can be used to assist in the design and analysis of vaccine trials and epidemiological studies.
Relevance to Public Health
Multiple candidate dengue vaccines are currently in development, however, their likely effectiveness over short
and long time periods remain unknown due to a lack of good markers of protection or risk. Identifying such
markers, and how they change over time is critical to their optimal use, continued efficacy and population safety.
More broadly, characterization of non-neutralizing antibody and cellular immune responses to a diverse set of
dengue viruses alongside neutralizing responses in humans followed over many years who have experienced
dengue infection and/or vaccination will increase our understanding of immune responses to dengue.
项目摘要
登革热在许多国家仍然是顽固的地方病。疫苗开发工作受到阻碍,
对免疫反应缺乏了解。我们知道,预先存在的免疫接种或
历史感染是推动疾病风险的关键,然而,缺乏准确的风险或保护标志,
包括它们多年来的变化。对非中和抗体的作用知之甚少
功能,如抗体依赖性细胞毒性和抗体依赖性增强驱动疾病
风险中和和非中和抗体反应尚未与细胞免疫反应一起表征。
免疫反应已被确定为与疾病的风险有关。在这里,我们将扩展到
先前关于中和反应多样性的工作专门增加了非中和反应的表征
来自自然感染和接种疫苗的抗体应答和细胞免疫应答,
同一个人在不同的时间点这些样本来自于那些定期
收集血清和PBMC,并跟踪感染和疾病的情况,其中许多是严重的。这
包括接种了唯一许可的登革热疫苗的一组个体,
13年我们还可以获得接种另一种候选疫苗的个体的样本,
超过五年。最后,我们将重新招募队列参与者,在他们参与23年后提供样本
研究感染后的长期反应。我们将测量多个非中和和中和
对各种登革热病毒的反应,广泛的抗体措施以及有限的
细胞免疫应答,提供体液和细胞免疫应答的多维系统表征,
免疫反应。我们将使用这种多维测量和数学模型来重建完整的
感染史和免疫动力学这些努力将提供一套保护/疾病风险的相关因素
和感染,可用于评估疫苗试验和流行病学研究的风险。这些机械
模型通常可用于推断对抗原可变病原体的免疫应答的动力学,
可用于协助疫苗试验和流行病学研究的设计和分析。
与公共卫生的相关性
目前正在开发多种候选登革热疫苗,然而,它们可能的有效性超过短期
并且由于缺乏良好的保护或风险标记,长时间内仍然未知。识别此类
标记物及其随时间的变化对它们的最佳使用、持续有效性和人群安全性至关重要。
更广泛地说,非中和抗体和细胞免疫反应的表征,以不同的一组,
登革热病毒以及人类的中和反应进行了多年的研究,
登革热感染和/或疫苗接种将增加我们对登革热免疫反应的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Derek A Cummings其他文献
Derek A Cummings的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Derek A Cummings', 18)}}的其他基金
Human mobility models to forecast disease dynamics and the effectiveness of public health interventions
用于预测疾病动态和公共卫生干预措施有效性的人员流动模型
- 批准号:
10390412 - 财政年份:2021
- 资助金额:
$ 69.11万 - 项目类别:
Human mobility models to forecast disease dynamics and the effectiveness of public health interventions
用于预测疾病动态和公共卫生干预措施有效性的人员流动模型
- 批准号:
10599117 - 财政年份:2021
- 资助金额:
$ 69.11万 - 项目类别:
Human mobility models to forecast disease dynamics and the effectiveness of public health interventions
用于预测疾病动态和公共卫生干预措施有效性的人员流动模型
- 批准号:
10228957 - 财政年份:2021
- 资助金额:
$ 69.11万 - 项目类别:
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISK
连接抗原
- 批准号:
8801344 - 财政年份:2015
- 资助金额:
$ 69.11万 - 项目类别:
Modeling interactions between HIV interventions in key populations in India
模拟印度重点人群艾滋病毒干预措施之间的相互作用
- 批准号:
8846213 - 财政年份:2015
- 资助金额:
$ 69.11万 - 项目类别:
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISK
连接抗原
- 批准号:
9012767 - 财政年份:2015
- 资助金额:
$ 69.11万 - 项目类别:
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISK
连接抗原
- 批准号:
9269963 - 财政年份:2015
- 资助金额:
$ 69.11万 - 项目类别:
Monitoring cause-specific school absences to estimate influenza transmission in W
监测特定原因的学校缺勤以估计西澳的流感传播情况
- 批准号:
8728607 - 财政年份:2013
- 资助金额:
$ 69.11万 - 项目类别:
Monitoring cause-specific school absences to estimate influenza transmission in W
监测特定原因的学校缺勤以估计西澳的流感传播情况
- 批准号:
9381264 - 财政年份:2013
- 资助金额:
$ 69.11万 - 项目类别:
Monitoring cause-specific school absences to estimate influenza transmission in W
监测特定原因的学校缺勤以估计西澳的流感传播情况
- 批准号:
8632337 - 财政年份:2013
- 资助金额:
$ 69.11万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 69.11万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 69.11万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 69.11万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 69.11万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 69.11万 - 项目类别: